Hagios Life Sciences Comprehensive Company Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 27-06-2024
- Paid Up Capital ₹ 0.10 M
as on 27-06-2024
- Company Age 12 years 9 months
- Last Filing with ROC 31 Mar 2022
- Revenue %
FY 2022
- Profit 96.31%
FY 2022
- Ebitda 97.75%
FY 2022
- Net Worth -1.11%
FY 2022
- Total Assets -2.48%
FY 2022
About Hagios Life Sciences
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2022. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per the Ministry of Corporate Affairs (MCA) records.
Vinodkumar Loh, Dineshkumar Chaudhary, and Pravinkumar Chaudhary serve as directors at the Company.
- CIN/LLPIN
U51397GJ2011PTC068325
- Company No.
068325
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
21 Dec 2011
- Date of AGM
30 Sep 2022
- Date of Balance Sheet
31 Mar 2022
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Company Details
- Location
Ahmedabad, Gujarat, India
- Telephone
- Email Address
- Website
-
- Social Media-
What products or services does Hagios Life Sciences Private Limited offer?
Hagios Life Sciences Private Limited offers a wide range of products and services, including Multivitamin Syrup & Drops, Haematinics Syrup, Antihistamines, Anti Cold Tablet, Antibiotic Tablets & Capsules, Azithromycin Tablets, Antibiotic Syrup & Oral Suspension, Azithromycin Suspension Syrup.
Who are the key members and board of directors at Hagios Life Sciences?
Board Members(3)
Financial Performance and Corporate Structure Insights of Hagios Life Sciences.
Hagios Life Sciences Private Limited, for the financial year ended 2022, experienced no change in revenue, with a 0% increase. The company also saw a substantial improvement in profitability, with a 96.31% increase in profit. The company's net worth dipped by a decrease of 1.11%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| FY 2022 | FY 2021 | FY 2020 | FY 2019 | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Hagios Life Sciences?
Unlock access to Hagios Life Sciences's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
7 years 6 months Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Hagios Life Sciences?
Unlock and access historical data on people associated with Hagios Life Sciences, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Hagios Life Sciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Hagios Life Sciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
